Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma

Gynecologic Oncology

Volumn 72, Issue 3, 1999, Pages 351-359

  Iwai, Kyoko ^a   Fukuda, Koichi ^a   Hachisuga, Toru ^b   Mori, Mitsuru ^a   Uchiyama, Michiko ^a   Iwasaka, Tsuyoshi ^a   Sugimori, Hajime ^a  

^a SAGA UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032981669     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5286     Document Type: Article

References (39)

1. Creasman W T. New gynecologic cancer staging. Obstet Gynecol. 75:1990;287-288.
2. DiSaia P J, Creasman W T, Boronow R C, Blessing J A. Risk factors and recurrent patterns in Stage I endometrial cancer. Am J Obstet Gynecol. 151:1985;1009-1015.
3. Belinson J L, Lee K R, Badger G J, Pretorius R G, Jarrell M A. Clinical stage I adenocarcinoma of the endometrium: Analysis of recurrence and the potential benefit of staging lymphadenectomy. Gynecol Oncol. 44:1992;17-23.
4. Faught W, Krepart G, Lotocki R, Heywood M. Should selective paraaortic lymphadenectomy be part of surgical staging for endometrial cancer. Gynecol Oncol. 52:1993;102.
5. Calais G, Descamps P, Vitu L, Body G, Lansac J, Bougnoux P, Floch O L. Is lymphadenectomy useful in the treatment of endometrial carcinoma. Gynecol Oncol. 38:1990;71-75.
6. Vardi J R, Tadros G H, Anselmo M T, Rafla S D. The value of exploratory laparotomy in patients with endometrial carcinoma according to the new International Federation of Gynecology and Obstetrics staging. Obstet Gynecol. 80:1992;204-208.
7. Larson D M, Johnson K K. Pelvic and para-aortic lymphadenectomy for surgical staging of high-risk endometrioid adenocarcinoma of the endometrium. Gynecol Oncol. 51:1993;345-348.
8. Girardi F, Petru E, Heydarfadai M, Haas J, Winter R. Pelvic lymphadenectomy in the surgical treatment of endometrial cancer. Gynecol Oncol. 49:1993;177-180.
9. Fanning J, Evans M C, Peters A J, Samuel M, Harmon E R, Bates J S. Endometrial adenocarcinoma histologic subtypes: Clinical and pathologic profile. Gynecol Oncol. 32:1989;288-291.
10. Ward B G, Wright R G, Free K. Papillary carcinomas of the endometrium. Gynecol Oncol. 39:1990;347-351.
11. Creasman W T, Morrow C P, Bundy B N, Homesley H D, Graham J E, Heller P. Surgical pathological spread patterns of endometrial cancer: A Gynecologic Oncology Group study. Cancer. 60:1987;2035-2041.
12. Christopherson W M, Connelly P J, Alberhasky R C. Carcinoma of the endometrium; V. An analysis of prognosticators in patients with favorable subtypes and Stage I disease. Cancer. 51:1983;1705-1709.
13. Mittal K R, Schwartz P E, Barwick K W. Architectural (FIGO) grading, nuclear grading, and other prognostic indicators in Stage I endometrial adenocarcinoma with identification of high-risk and low-risk groups. Cancer. 61:1987;538-545.
14. Boronow R C. Advances in diagnosis, staging, and management of cervical and endometrial cancer, stages I and II. Cancer. 65:1990;648-659.
15. Ambros R A, Kurman R J. Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus. Cancer. 69:1992;1424-1431.
16. Morrow C P, Bundy B N, Kurman R J, Creasman W T, Heller P, Homesley H D, Graham J E. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group Study. Gynecol Oncol. 40:1991;55-65.
17. Ehlich C E, Young P CM, Stehman F B, Sutton G P, Alford W M. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol. 158:1988;796-807.
18. Creasman W T. Prognostic significance of hormone receptors in endometrial cancer. Cancer. 71:1993;1467-1470.
19. Morris P C, Anderson J R, Anderson B, Buller R E. Steroid hormone receptor content and lymph node status in endometrial cancer. Gynecol Oncol. 56:1995;406-411.
20. Yamauchi N, Sakamoto A, Uozaki H, Iihara K, Machinami R. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int J Gynecol Pathol. 15:1996;202-208.
21. Pertschuk L P, Masood S, Simone J, Feldman J G, Fruchter R, Axiotis C A, Greene G L. Estrogen receptor immunocytochemistry in endometrial carcinoma: A prognostic marker for survival. Gynecol Oncol. 63:1996;28-33.
22. Fukuda K, Mori M, Uchiyama M, Iwai K, Iwasaka T, Sugimori H. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol. 69:1998;220-225.
23. Ambros R A, Kurman R J. Identification of patients with Stage I uterine endometrioid adenocarcinoma at high risk of recurrence by DNA ploidy, myometrial invasion, and vascular invasion. Gynecol Oncol. 45:1992;235-239.
24. Lukes A S, Kohler M F, Pieper C F, Kerns B J, Bentley R, Rodriguez G C, Soper J T, Clarke-Pearson D L, Bast R C, Berchuck A. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer. 73:1994;2380-2385.
25. Pisani A L, Barbuto D A, Chen D, Ramos L, Lagasse L D, Karlan B Y. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol. 85:1995;729-734.
26. Bell J G, Minnick A, Reid G C, Judis J, Brownell M. Relationship of nonstaging pathological risk factors to lymph node metastasis and recurrence in clinical stage I endometrial carcinoma. Gynecol Oncol. 66:1997;388-392.
27. Khalifa M A, Mannel R S, Haraway S D, Walker J, Min K W. Expression of EGFR, HER-2/neu, p53, and PCNA in endometrioid serous papillary, and clear cell endometrial adenocarcinoma. Gynecol Oncol. 53:1994;84-92.
28. Hamel N W, Sebo T J, Wilson T O, Keeney G L, Roche P C, Suman V J, Hu T C, Podratz K C. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol Oncol. 62:1996;192-198.
29. Schofield J B, Mansi J, Camplejohn R S, Lane D P, Fisher C. Proliferating cell nuclear antigen and S phase fraction in endometrial stromal sarcoma. J Clin Pathol. 45:1992;263-267.
30. Yu C CW, Wilkinson N, Brito M J, Buckley C H, Fox H, Levison D A. Patterns of immunohistochemical staining for proliferating cell nuclear antigen and p53 in benign and neoplastic human endometrium. Histopathology. 23:1993;367-371.
31. Inoue M, Okayama A, Fujita M, Enomoto T, Sakata M, Tanizawa O. Clinicopathological characteristics of p53 overexpression in endometrial cancers. Int J Cancer. 58:1994;14-19.
32. Soong R, Knowles S, Williams K E, Hammond I G, Wysocki S J, Iacopetta B J. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer. 74:1996;562-567.
33. Kohlberber P, Gitsch G, Loesch A, Tempfer C, Kaider A, Reinthaller A, Kainz C, Breitenecker G. p53 protein overexpression in early stage endometrial cancer. Gynecol Oncol. 62:1996;213-217.
34. Kohler M F, Carney P, Dodge R, Soper J T, Clarke-Pearson D L, Marks J R, Berchuck A. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol. 175:1996;1246-1252.
35. Levine A J, Momand J, Finley K A. The p53 tumour suppressor gene. Nature. 351:1991;453-456.
36. Bravo R, Frank R, Blundell P A, Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature. 326:1987;515-517.
37. Pertschuk L P, Kim D S, Nayer K, Feldman J G, Eisenberg K B, Carter A C, Rong Z T, Thelmo W L, Fleisher J, Greene G L. Immunocytochemical estrogen and progesterone receptor assays in breast cancer with monoclonal antibodies: Histopathologic, demographic and biochemical correlations and relationship to endocrine response and survival. Cancer. 66:1990;1663-1670.
38. SAS Institute, Inc. SAS/STAT Software: CALIS and LOGISTIC Procedures, Release 6.04, Cary, NC, SAS Institute, 1990.
39. Boronow R C, Morrow C P, Creasman W T, DiSaia P J, Silverberg S G, Miller A, Blessing J A. Surgical staging in endometrial cancer: Clinical-pathologic findings of a prospective study. Obstet Gynecol. 63:1984;825-832.